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Abstract
Background: Pituitary tumor transforming gene (pttg) is a novel oncogene that is expressed at higher level in most of the tumors
analyzed to date compared to normal tissues. Nevertheless, its expression in prolactinomas and its relation with the pituitary
dopamine receptor 2 (D2R) are not well defined. We sought to determine the pituitary level of pttg in three different experimental
models of prolactinomas with altered dopaminergic control of the pituitary: the dopaminergic D2R knockout female mouse, the
estrogen-treated rat, and the senescent female rat. These three models shared the characteristics of increased pituitary weight,
hyperprolactinemia, lactotrope hyperplasia and reduced or absent dopaminergic action at the pituitary level. We also studied
samples from human macroprolactinomas, which were characterized as responsive or resistant to dopamine agonist therapy.
Results:  When compared to female wild-type mice, pituitaries from female D2R knockout mice had decreased PTTG
concentration, while no difference in pttg mRNA level was found. In senescent rats no difference in pituitary PTTG protein
expression was found when compared to young rats. But, in young female rats treated with a synthetic estrogen (Diethylstylbestrol,
20 mg) PTTG protein expression was enhanced (P = 0.029). Therefore, in the three experimental models of prolactinomas, pituitary
size was increased and there was hyperprolactinemia, but PTTG levels followed different patterns.
Patients with macroprolactinomas were divided in those in which dopaminergic therapy normalized or failed to normalize prolactin
levels (responsive and resistant, respectively). When pituitary pttg mRNA level was analyzed in these macroprolactinomas, no
differences were found.
We next analyzed estrogen action at the pituitary by measuring pituitary estrogen receptor α levels. The D2R knockout female
mice have low estrogen levels and in accordance, pituitary estrogen receptors were increased (P = 0.047). On the other hand, in
senescent rats estrogen levels were slightly though not significantly higher, and estrogen receptors were similar between groups.
The estrogen-treated rats had high pharmacological levels of the synthetic estrogen, and estrogen receptors were markedly lower
than in controls (P < 0.0001). Finally, in patients with dopamine resistant or responsive prolactinomas no significant differences in
estrogen receptor α levels were found. Therefore, pituitary PTTG was increased only if estrogen action was increased, which
correlated with a decrease in pituitary estrogen receptor level.
Conclusion: We conclude that PTTG does not correlate with prolactin levels or tumor size in animal models of prolactinoma, and
its pituitary content is not related to a decrease in dopaminergic control of the lactotrope, but may be influenced by estrogen action
at the pituitary level. Therefore it is increased only in prolactinomas generated by estrogen treatment, and not in prolactinomas
arising from deficient dopamine control, or in dopamine resistant compared with dopamine responsive human prolactinomas. These
results are important in the search for reliable prognostic indicators for patients with pituitary adenomas which will make tumor-
specific therapy possible, and help to elucidate the poorly understood phenomenon of pituitary tumorigenesis.
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Background
Pituitary tumors rarely produce metastasis, but cause con-
siderable morbidity and mortality. Prolactinomas are the
more prevalent among pituitary tumors. They are usually
benign, and can be effectively treated with dopaminergic
agents. Nevertheless, 15% of them may be or become
resistant to classical pharmacological therapy, can be
invasive, and require extirpation. In general, pituitary
tumors result from monoclonal growth and intrinsic
genetic defects which are related to oncogenes, suppressor
genes, and genes responsible of differentiation [1]. On the
other hand, growth factors of hypothalamic or pituitary
origin may act on aberrant cells, contributing to their pro-
liferation. [2]. Point mutations identified up to date can
only account for a small percentage of pituitary tumors,
and the mechanism of pituitary tumorigenesis is still
unraveling.
Pituitary tumor transforming gene (pttg) is a recently
cloned oncogene that was identified in rat pituitary tumor
cells by differential mRNA display [3]. It has been pro-
posed as an important paracrine growth factor involved in
early lactotrope transformation and onset of angiogenesis
in pituitary hyperplasia in estrogen-treated rats [4]. PTTG
(protein encoded by pttg) has been recognized as a mam-
malian securin that maintains binding of sister chromati-
des during mitosis [5]. PTTG must be proteolysed during
cell division for sister chromatid separation to occur, and
failure in this process, as in PTTG overexpression, elicits
inappropriate sister chromatid exchange, resulting in
genetic instability as an early tumorigenic event [6].
Several lines of evidence support the role of PTTG in tum-
origenesis [6,7]. Overexpressed PTTG induces cell aneu-
ploidy, transforms NIH3T3 cells in vitro and  in vivo,
stimulates basic fibroblast growth factor (FGF-2) produc-
tion, and stimulates proliferation and angiogenesis. Fur-
thermore, PTTG transactivates the oncogene c-myc, which
in turn may influence cell growth [6]. PTTG is expressed
in high levels in different pituitary tumors [8] and other
neoplasms including carcinomas of lung, breast, colon,
thyroid, adrenal, liver, kidney, endometrium, uterus,
ovary leukemia and lymphomas [9]. The expression of
PTTG in normal tissues is restricted, with highest expres-
sion in the testis.
The role of PTTG in prolactinomas is not clear, further-
more, the relation of PTTG expression and dopamine con-
trol of pituitary function has not been established. We
sought to determine the level of PTTG expression in three
different experimental models of lactotrope hyperplasia
with altered dopaminergic control of lactotropes: the
dopaminergic D2R knockout female mouse [10], the
estrogen-treated rat [11], and the senescent female rat
[12]. These three models share the characteristics of a
tumoral pituitary, hyperprolactinemia, lactotrope hyper-
plasia and reduced or absent dopaminergic action at the
pituitary level [13,13-16]. We also studied human prolac-
tinoma tissue from patients who were characterized as
responsive or resistant to dopamine agonist therapy.
We believe that the elucidation of the factors involved in
the regulation of lactotrope proliferation and pituitary
angiogenesis might open new possibilities in the treat-
ment of prolactinomas, especially in those cases with
resistance or intolerance to dopamine agonists.
Results
PTTG levels in pituitaries from animal models of 
prolactinoma
PTTG protein and mRNA expression were determined in
the lactotrope hyperplasia of the D2R female knockout
mouse. When compared to female wild-type mice, pitui-
taries from female D2R knockout mice had decreased
PTTG concentration (normalized to actin content, Figure
1A,  P  = 0.00057), while no differences in pttg mRNA
expression were found (normalized to the housekeeping
gene GAPDH, Figure 1B). Knockout mice had increased
pituitary weight as previously described [10], and as
expected, serum prolactin levels were greatly increased in
knockout when compared to wildtype mice (Table 1).
In senescent rats no difference in pituitary PTTG protein
expression was found when compared to young rats (Fig-
ure 2A). Old rats had increased pituitary weight and ele-
vated prolactin levels (Table 1). Hyperprolactinemia and
hypertrophy of the gland were lower than those observed
in the D2R knockout mouse.
In young female rats treated with a synthetic estrogen
(DES 20 mg) pituitary weight and serum prolactin levels
were increased as expected (Table 1), and PTTG protein
expression was enhanced as well (P = 0.029, Figure 2B).
Therefore, in the three experimental models of prolactin-
omas pituitary size was increased and there was hyperpro-
lactinemia, but PTTG expression followed different
patterns.
PTTG levels in macroprolactinomas from dopamine 
agonist responsive or resistant patients
Patients with prolactinomas were divided in those in
whom dopaminergic therapy normalized or failed to nor-
malize prolactin levels (responsive and resistant, respec-
tively, Figure 3A). When pituitary pttg mRNA expression
was analyzed in these macroprolactinomas, comparing
resistant adenomas with those responding to dopaminer-
gic pharmacological treatment, no differences were found
(Figure 3B).Molecular Cancer 2007, 6:4 http://www.molecular-cancer.com/content/6/1/4
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Estrogen Receptor α levels in animal and human 
prolactinomas
We next analyzed serum estrogen levels, and pituitary
estrogen receptor α levels. In D2R knockout mice estrogen
levels and action are lower than in wildtype mice and
fewer estral cycles are observed; in accordance, pituitary
estrogen receptors were increased (P = 0.047, Figure 4A).
On the other hand, in senescent rats estrogen levels were
slightly though not significantly higher (Young 28.9 ± 2.6
and old 36.5 ± 1.8 pg/ml, NS), and estrogen receptors
were similar between groups Figure 4B).
The estrogen treated rats had high pharmacological levels
of the synthetic estrogen, and estrogen receptors were
markedly lower than in controls (P < 0.0001, Figure 4C).
Finally, in patients with dopamine resistant prolactino-
mas, we found similar estrogen receptor α levels when
compared to responsive tumors, even though there was a
tendency to higher levels in resistant prolactinomas (Fig-
ure 5).
Evaluating the results of all groups, we observed that pitu-
itary PTTG was increased only if estrogen action was
increased, which correlated with a decrease in pituitary
estrogen receptor level. We therefore conclude that PTTG
does not correlate with prolactin levels in prolactinomas,
and is not related to a decrease in dopaminergic control of
Table 1: Pituitary weight, serum prolactin and estrogen levels in the three experimental models of prolactinomas.
Pituitary weight (mg) P < serum prolactin (ng/ml) P < serum estrogens
Wildtype mouse 2.51 ± 0.34 0.001 29.1 ± 6.6 0.001 normal
D2R KO mouse 7.03 ± 1.39 272.8 ± 59.7 low
Young rat 11.3 ± 0.5 0.01 24.3 ± 3.2 0.01 28.9 ± 2.6 pg/ml
Senile rat 20.2 ± 6.2 98.3 ± 20.8 36.5 ± 1.8 pg/ml
Control oil- injected rat 14.7 ± 0.3 0.001 9.4 ± 1.7 0.001 normal
DES injected rat 43.6 ± 3.7 444.0 ± 41.7 high
Comparative PTTG and pttg mRNA content in pituitaries from wildtype and D2R knockout female mice Figure 1
Comparative PTTG and pttg mRNA content in pituitaries from wildtype and D2R knockout female mice. A) 
Comparative pituitary PTTG content (evaluated by Western blot) in wildtype (+/+, filled bars) and D2R knockout (-/-, empty 
bars) female mice. For each sample, arbitrary units of band intensities for PTTG were divided by band intensities for the 
respective actin, and compared to those of wildtype females (considered 100%) in each series of experiments. * P < 0.05 vs. +/
+; N = 12 and 15, respectively. For this and following figures, results shown are means ± SE. Below, representative western 
blots. B) Densitometric analysis of pituitary pttg RT-PCR products, in wildtype (filled bars) and D2R knockout (empty bars) 
female mice. For each sample, intensity units of the pttg band were normalized to those of the respective GAPDH band. * P < 
0.05 vs. +/+; N = 5 and 5. Below representative bands are depicted.
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Serum prolactin levels and PTTG mRNA in prolactinomas in dopamine agonist responsive or resistant patients Figure 3
Serum prolactin levels and PTTG mRNA in prolactinomas in dopamine agonist responsive or resistant 
patients. A: Serum prolactin levels in responsive and resistant patients with prolactinomas after prolonged dopaminergic ther-
apy (see Materials and Methods). N = 6 and 14, * P < 0.05. B: Comparative pituitary pttg mRNA content (evaluated by real time 
PCR) in patients with macroprolactinomas. N = 6 for Responsive patients (patients with normalization of prolactin levels after 
dopaminergic treatment), and N = 14 for patients resistant to such therapy.
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Comparative pituitary PTTG content in young and old rats, and in control and DES-injected female rats Figure 2
Comparative pituitary PTTG content in young and old rats, and in control and DES-injected female rats. Com-
parative pituitary PTTG content (evaluated by Western blot) in young and old rats (A: stippled bars) and control and DES-
injected female rats (B: dotted bars). For each sample, arbitrary units of band intensities for PTTG were divided by band inten-
sities for the respective actin band intensity, and compared to those of young (A) or control (B) females (considered 100%) in 
each series of experiments. * P < 0.05 vs. young or control respectively; N = 5 and 5 for A), and 12 and 12, for B). Inset: repre-
sentative bands.
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the lactotrope, but is sensitive to estrogen action at the
pituitary level.
Discussion
Pituitary tumor-transforming gene isolated by differential
display from GH-secreting pituitary tumor cell lines [3], is
expressed in actively proliferating normal tissue specially
the testis and lymphopoietic system, as well as in several
tumor types. In particular, it is ubiquitously expressed in
pituitary tumors at higher levels than those detected in
normal pituitary. PTTG is required for tissue self-renewal
and pttg-null mice have hypoplastic testes, spleen, and
pituitary glands [17]. Furthermore, PTTG overexpression
results in focal pituitary hyperplasia and adenoma forma-
tion [18].
Nevertheless the expression of pttg in prolactinomas, and
in particular, in dopamine resistant prolactinomas has
not been well defined. In humans, pttg overexpression in
pituitary tumors has been demonstrated [19-21], but con-
troversies on correlation between pttg levels and tumor
behaviour or type exist. Higher pttg expression was
detected in somatotrope tumors [19,21] and non func-
tioning adenomas in comparison to other hormone
secreting pituitary tumors [21], and pttg correlated with
GH secretion in one study [19]. In another study, pttg was
also highly expressed in nonfunctioning and in GH-
secreting tumors but there was, in general, an ubiquitous
presence of high pttg in most pituitary adenomas, and in
particular, increased pttg was observed in hormone-secret-
ing tumors that had invaded the sphenoid bone [8].
Finally, in some studies there was no correlation of pttg
levels and imaged tumor volume or invasiveness [19,21].
In rats, on the other hand, pttg is clearly involved in early
pituitary lactotrope tumors induced by pharmacological
administration of estrogens [4].
Our results show that increased PTTG or pttg mRNA is not
a common feature of lactotrope hyperplasia in experimen-
tal rodent models with decreased pituitary dopaminergic
function, or in human dopamine agonist resistant com-
pared with responsive prolactinomas. Nevertheless, PTTG
Pituitary ERα in human responsive and resistant macroprol- actinomas Figure 5
Pituitary ERα in human responsive and resistant 
macroprolactinomas. Comparative pituitary ERα mRNA 
evaluated by real time PCR in human responsive and resist-
ant macroprolactinomas. N = 4,10.
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protein expression is sensitive to high estrogen levels,
which decreases dopaminergic control of the lactotrope.
The D2R female knockout mouse is an excellent model to
study pituitary dopamine resistance. Dopamine is the
principal hypothalamic inhibitory factor for lactotrope
cells. Its main receptor in the pituitary is the D2R, and
therefore these knockout mice develop lactotrope hyper-
plasia [13] followed by lactotrope tumor formation [22].
Pituitary glands of the female D2R knockout mice have
markedly increased number of cells containing prolactin
[23]. These lactotropes were hyperstimulated with rapid
turnover of prolactin and limited storage capacity. Fur-
thermore, we found that the expression of the angiogenic
protein, vascular endothelial growth factor-A (VEGF), was
increased in pituitaries from D2R knockout female mice,
and increased pituitary VEGF expression was mainly
dependent on the lack of dopaminergic control [24]. In
the present work we show that PTTG, another angiogenic
protein, is not increased in the proliferating pituitary
gland of the D2R knockout mouse. This would suggest
that PTTG is not regulated by dopamine. Furthermore, we
found low expression of PTTG in D2R knockout com-
pared to wildtype mice despite similar pttg transcripts.
This could suggest a post-translational regulation of PTTG
(e.g. an increased degradation of PTTG within the ubiqui-
tin proteasome system in knockouts) that could be part of
a protective mechanism against tumor development in
the setting of lactotrope hyperplasia. On the other hand,
these knockout mice have a low estrogenic environment.
High prolactin levels throughout life [10] are certainly
related to the relative infrequent estral cycles observed in
these mice, which cease to reproduce around the fourth
month of life. Therefore, low estrogenic input at the pitu-
itary level may be insufficient to promote pttg expression.
In the female rat, we have shown that aging is character-
ized by a high incidence of prolactin secreting pituitary
adenomas and diffuse prolactin cell hyperplasia [12,25].
These changes cannot be accounted for by different serum
profiles of gonadal steroids [25]. Estrogen levels were not
significantly increased in aging rats, even though we
found a marked enlargement of the pituitary gland. On
the other hand, aging brings about a progressive loss of
both tuberoinfundibular dopaminergic system and periv-
entricular dopaminergic system neurons [16], which may
contribute significantly to lactotrope hyperplasia. There
are no reports in the literature with regard to the pituitary
expression of angiogenic growth factors in senescence. We
found that the pituitary content of PTTG was similar in
senescent and young rats, indicating that this protein is
not involved in the age-related hyperplastic progression of
lactotropes in aging female rats.
Chronic administration of estrogens to rats induces
enlargement of the anterior pituitary and increases the
synthesis and secretion of prolactin [11]. Histologically,
the resulting tumors are composed of hyperplastic and
hypertrophied lactotropes [26]. Damage to hypothalamic
dopaminergic neurones in response to estrogen [14] as
well as a direct action of estrogen at the pituitary level
decreasing dopamine sensitivity [27,28] have been pro-
posed as causative factors. Besides, the effect of estrogen
can be accounted for by alterations in different growth fac-
tors: VEGF, and FGF-2 [4,29,30], even though increases in
such growth factors do not necessarily imply their strict
requirement for tumor development [31]. In accordance
with the literature, we describe a marked increase in pitu-
itary PTTG expression in the estrogen-treated rats.
PTTG was initially proposed as an angiogenic and/or
oncogenic factor in human pituitary tumors [32]. In fact,
abundant and concordant PTTG and bFGF expression in
different human pituitary tumors was described [4]. Fur-
thermore, anti-estrogens reduced PTTG expression in
human pituitary tumors in vitro (three gonadotroph, five
nonfunctioning) and suppressed experimental tumor
growth in vivo [29]. But, we describe that PTTG expression
is not increased in human dopamine resistant when com-
pared to dopamine responsive prolactinomas. This is con-
sistent with experimental animal results presented herein
which demonstrate that reduced dopaminergic action at
the pituitary is associated with pituitary enlargement,
hyperprolactinemia but not necessarily with increased
PTTG expression.
Therefore, taken together, our results suggest that PTTG
increment in estrogen-induced prolactinomas is not
related to the deficient dopaminergic control of the pitui-
tary found in this model, but to another estrogenic path-
way.
We measured pituitary estrogen receptors in order to
establish a link with circulating estrogen and pituitary
PTTG expression. Cellular estrogen receptor levels are
dynamic and are particularly sensitive to changes in circu-
lating levels of 17β-estradiol. The level of steroid receptors
in cells changes with varying physiological states. In most
cases, the primary endocrine regulator is the ligand itself.
In an autoregulatory feedback loop, estrogen induces a
decline in both ERα protein and mRNA in lactotrope cells.
It has been demonstrated through a number of studies
that the decline in ERα upon exposure to 17β-estradiol
results from a combination of mechanisms that control
both receptor synthesis and degradation through tran-
scriptional, posttranscriptional, and posttranslational
mechanisms [33,34]. The most rapid of these regulatory
mechanisms is the direct loss of ERα protein brought
about by the induction of proteasome-mediated proteol-Molecular Cancer 2007, 6:4 http://www.molecular-cancer.com/content/6/1/4
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ysis [35]. Our results show that the only experimental
model with low pituitary estrogen receptors was the estro-
gen-treated rat, indicating a down regulating effect of the
pharmacological administration of the synthetic estrogen.
On the other hand, in the pituitary of the D2R knockout
female mouse estrogen receptors were high when com-
pared to their wildtype counterparts, indicating reduced
serum levels of estradiol which correlate with the reduced
fertility of these mice, and with results of another D2R
knockout mouse [36]. In aging rats neither pituitary estro-
gen receptor levels nor serum estrogen levels were signifi-
cantly different from young rats. And finally, in the
pituitaries from human prolactinomas estrogen receptors
were not significantly different between responsive and
resistant tumors.
So even though PTTG expression is increased in rapidly
proliferating cells in some experimental models support-
ing that it may play a role in the control of cell prolifera-
tion, we postulate that it does not participate in the
prolactinoma development caused by deficient dopamine
control of the lactotrope. Emerging data clearly indicate
that different molecular mechanisms are involved in the
pathogenesis of the various pituitary tumor subtypes, and
PTTG may be increased in somatotropinomas and other
pituitary tumors, but not in dopamine resistant in com-
parison to dopamine sensitive prolactinomas, and it is
not regulated by dopamine in different experimental pro-
lactinomas. On the other hand, high estrogen levels could
impact on PTTG expression. Finding reliable prognostic
indicators for patients with pituitary adenomas will make
tumor-specific therapy possible, and elucidation of the
particular oncogenes or growth factors involved in each
pituitary tumor subtype will be fundamental to determin-
ing the poorly understood phenomenon of pituitary tum-
origenesis.
Methods
Animals
A) D2 dopamine receptor female knockout mice (KO)
(official strain designation B6; 129S2-Drd2tm1low by the
Induced Mutant Resource at The Jackson Laboratory, Bar
Harbor, ME), generated by targeted mutagenesis of the
D2R gene in embryonic stem cells [13,22] were used. The
original F2 hybrid strain (129S2/Sv × C57BL/6J) contain-
ing the mutated D2R allele was backcrossed for eight gen-
erations to wild-type C57BL/6J mice (WT). Mutant and
wild-type mice were generally the product of heterozygote
crossings, and in all cases sibling controls were used. Mice
were housed in groups of 4 or 5 with mixed genotypes in
an air-conditioned room with lights on at 0700 and off at
1900 h. They had free access to laboratory chow and tap
water. Wild-type, heterozygous and knockout mice were
identified by PCR of genomic DNA, as previously
described [10]. Animals were used at 6–8 months. All
experimental procedures were reviewed and approved by
the institutional animal care and use committee of the
Instituto de Biología y Medicina Experimental, Buenos
Aires (Division of Animal Welfare, Office for Protection of
Research Risks, National Institutes of Health, A#5072-
01).
B) Senescent rats
Young (5 mo) and senescent (28–31 mo) female Sprague-
Dawley rats, raised in the gerontological rat colony of
INIBIOLP, Universidad de La Plata, Buenos Aires, were
used. Animals were housed in a temperature-controlled
room (22 ± 2°C) on a 14:10 h light/dark cycle. Food and
water were available ad libitum. In our colony, the average
50% survival time for females, studied in groups of 50–60
animals, is 33 months (range 32–34 mo).
C) Rats with DES treatment
Female 60-day-old Sprague-Dawley rats were divided into
two treatment groups (each of seven animals). Pituitary
tumors were induced by sc implantation of a 20 mg pellet
of diethylstilbestrol (DES group) (Sigma Mo) for seven
weeks, in one group, and the other group was used as con-
trol.
Patients with dopamine responsive and resistant 
prolactinomas
Following ethical approval and patient consent, tissue of
20 macroprolactinomas from patients submitted to sur-
gery were studied (14 women and 6 men, mean age at
diagnosis 23.4 ± 1.7 and 39.5 ± 4.4, respectively). The
removed tissues were quickly frozen in liquid nitrogen
and stored at -80°C for subsequent molecular studies.
Patients were followed at the Hospital das Clinicas, Uni-
versity of Sao Paulo Medical School, Sao Paulo, Brazil.
Before starting dopaminergic treatment, average serum
prolactin level was 2302 µg/L, ranging from 70.0–16000
µg/L. Patients were divided as responsive (N = 6) and
resistant (N = 14) to dopamine agonist therapy, taking in
consideration prolactin normalization after pharmaco-
logical treatment. The 3 responsive patients in whom fol-
low up data was available were treated for 55 months
(range 3–83 mo) with a mean bromocriptine dose of
10.83 mg/day (range, 5–17.5 mg/day). In these patients
the mean lower prolactin levels during treatment was
11.03 ug/L. Resistant patients were treated for 20,5
months (range 3–63 months), and the mean lowest prol-
actin levels during treatment was 306.95 µg/L. Surgery
indication, besides prolactinoma dopamine agonist
resistance were tumor expansion, visual field defects and
headache, or intolerance to medical treatment
Drugs
Unless otherwise specified, all chemicals were purchased
from Sigma (St. Louis, MO).Molecular Cancer 2007, 6:4 http://www.molecular-cancer.com/content/6/1/4
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RIAs
Mouse and rat serum prolactin were measured by RIA
using kits provided by the National Institute of Diabetes
and Digestive and Kidney Diseases [NIDDK; Dr. A.F. Par-
low, National Hormone and Pituitary Program (NHPP),
Torrance, CA]. Results are expressed in terms of mouse
prolactin RP3 and rat prolactin RP3. Intra- and interassay
coefficients of variation were 7.2% and 12.8%, and 6.5%
and 11.5% respectively.
17β-estradiol was measured by RIA using commercial
solid phase kits (Coat-A-Count, DPC, Los Angeles, CA)
Human serum PRL was determined between 0800 and
1100 h, by a immunofluorimetric assay (Wallac AutoDEL-
FIA. PerkinElmer Life Sciences. Boston, MA). The normal
references values ranged from 2 to 10 µg/liter for men and
2 to 15 µg/liter for women. Intra- and interassay coeffi-
cients of variation were 1.05 and 2.60%, respectively
Western blot
Anterior pituitaries from mice or rats were homogenized
in 80 µl ice-cold buffer containing 60 mM Tris-HCl, 1 mM
EDTA (pH 6.8) and a mix of protease inhibitors (phenyl-
methyl-sulphonile, TPCK, TAME, ZPCK and TLCK) in a
handheld microtissue homogenizer. The homogenate was
then centrifuged at 800 × g for 5 min at 4°C. An aliquot
of supernatant was taken to quantify proteins by the
Lowry method. Thirty micrograms of proteins in 10 µl of
homogenization buffer were mixed with 10 µl 2× sample
buffer (60 mM Tris-HCl, 4 % sodium dodecyl sulfate
(SDS), 20 % glycerol, 0.02% bromophenol blue and 50
mM dithiotreitol (pH 6.8). Samples were sonicated dur-
ing 20 sec, heated 5 min at 95°C and subjected to 12%
SDS-polyacrylamide gel electrophoresis. The gel was then
blotted onto a nitrocellulose membrane (Bio-Rad) and
probed with the corresponding primary antibody fol-
lowed by a secondary antibody conjugated with horserad-
ish peroxidase. Polyclonal rabbit pttg antibody (1:1,000,
sc-5846, Santa Cruz Biotechnology or antibody provided
by S.S. Kakar) was used. Estrogen receptor-α (ERα MC-20,
sc-542 was purchased from Santa Cruz Biotechnologies).
Mouse monoclonal actin antibody (Ab-1) was purchased
from Labvision Co. (Freemont, CA). Immunoreactive
proteins were detected by enhanced chemoluminiscence
(Amersham, Aylesbury, UK). For repeated immunoblot-
ting, membranes were incubated in stripping buffer (62.5
mM Tris, 2 % SDS and 100 mM mercaptoethanol, pH 6.7)
for 40 min at 50°C and reprobed. Band intensities were
quantified using the ImageQuant software.
Preparation of mouse pituitary RNA
Total RNA was isolated from anterior pituitaries using
TRIzol Reagent (Gibco). Each gland was homogenized in
100 µl TRIzol, sonicated for 10 sec, and incubated at room
temperature for 5 min. Chloroform (20 µl) was added,
samples were shaken vigorously, and after 5 min of incu-
bation at room temperature, they were centrifuged at
12,000 × g for 15 min at 4°C. Isopropanol (50 µl) was
added to the supernatant to precipitate the RNA. After 10-
min incubation at room temperature, samples were cen-
trifuged at 12,000 × g for 10 min at 4°C, supernatants dis-
carded, and their pellets washed with 100 µl of 70%
ethanol. The resulting precipitates were resuspended in 5
ul diethylpyrocarbonate-treated water. RNA was quanti-
fied by UV spectrophotometry and its integrity checked by
gel electrophoresis.
Semiquantitative RT-PCR for mouse samples
Total RNA (150 ng) was reverse transcribed in a reaction
mixture containing 50 mM Tris-HCl (pH 8.3), 75 mM
KCl, 3 mM MgCl2, 10 mM dithiotreitol, 1 mM deoxynu-
cleotide triphosphates (dNTPs), 8 U RNAse inhibitor
(Promega, Madison, WI), 1 µg of random hexamers (Bio-
dynamics SRL, Buenos Aires, Argentina) and 200 U Molo-
ney murine leukemia virus transcriptase (Invitrogen Life
Technologies, Buenos Aires, Argentina) in a final volume
of 20 µl. After incubation at 37°C for 60 min, samples
were heated for 10 min at 70°C to inactivate the tran-
scriptase. The product was amplified with mouse pttg and
GAPDH sense and antisense primers in a reaction mixture
(30 µl) containing 2 mM Tris-HCl (pH 8.0), 1.5 mM KCl,
MgCl2, 0.2 mM dNTPs, 0.33 µM of each primer, and 2.5
U Taq DNA polymerase (Invitrogen Life Technologies),
using an Eppendorf thermal cycler.
In Table 2 primer sequences are detailed. Common steps
were a hot start step of 3 min at 95°C, followed by n cycles
of denaturation at 94°C for 60 sec, annealing at an ade-
quate temperature (see Table 2) for 60 sec, and extension
at 72°C for 50 sec, with a final elongation step of 5 min at
72°C.
Preliminary experiments using various RNA concentra-
tions and cycle numbers confirmed that these PCR reac-
tions were performed within the linear phase of the PCR
amplification reaction and the amplified product was
analyzed by 1.8 % agarose gel electrophoresis. Bands were
detected by ethidium bromide staining. Densitometric
analysis was conducted using the Scion Image software
and intensity values of pttg PCR products were normal-
ized to the corresponding GAPDH products.
RNA Isolation and Reverse Transcriptase Reaction from 
human samples
Tumor tissue stored in liquid nitrogen was fragmented in
a tissue pulverizer (Mikro-Dismembranator, B. Braun Bio-
tech International, Melsungen, Germany). Total RNA was
extracted from approximately 100 mg tissue after homog-
enization, using the Trizol reagent (Invitrogen, Carlsbad,Molecular Cancer 2007, 6:4 http://www.molecular-cancer.com/content/6/1/4
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USA) according to the manufacturer's recommendations.
The RNA concentration (1.7–1.8) was measured by UV
spectrophotometry at 260 nm. Only samples with
OD260/280 ratio >1.7 were further processed. RNA integ-
rity was assessed by 1% agarose gel electrophoresis in the
presence of ethidium bromide.
One µg total RNA was then retrotranscribed into a reac-
tion mixture (40 µl) containing 100 U Moloney murine
leukemia virus reverse transcriptase (Amersham Pharma-
cia Biotech,), 1× reaction buffer (Amersham), 0.2 mM
deoxynucleotide triphosphates (Promega,), 50 pmol
oligo(dT) primers (Invitrogen, Life technologies), 20 U
ribonuclease inhibitor (Promega). The reaction was car-
ried out at 37°C for 60 min then at 95°C for 5 min.
Real-Time PCR
Gene-specific primers for tested genes are presented in
Table 2. The relative quantification was given by the Ct
values, determined in duplicate reactions for test and ref-
erence samples for the target and for the internal control
gene (GAPDH). Duplicate Ct values were averaged and
the GAPDH subtracted to obtain DCt [DCt = Ct (target
gene) - Ct (GAPDH gene)]. DCt values were calculated for
each gene and reference sample. Relative expression level
was determined as 2-DDCt, where DDCt = DCt (target
sample) - DCt (reference sample). For the reference sam-
ple, DDCt equals 0 and 20 equals 1, so the fold change in
the reference sample equals 1 by definition. For the
unknown samples, evaluation of 2-DDCt indicates the
fold change in gene expression relative to the reference
sample. Values were expressed as n-fold differences in tar-
get gene expression. The reactions were prepared accord-
ing to standard protocols for one-step QuantiTect SYBR
Green RT-PCR (Qiagen): SYBR Green amplification mix-
tures (20 µl) contained 10 µL of 2× QuantiTect SYBR
Green RT-PCR Master Mix, 1.0 µM of each forward and
reverse primer, 0.2 µL of QuantiTect RT and 80 ng tem-
plate DNA. The cycling conditions were as follows: 30
min at 50°C, 95°C for 15 min, 40–50 cycles at 95°C for
20 s, 55–63°C for 30 s and 72°C for 30 s before a final
primer sequence extension incubation at 72°C or 5 min
(number of cycles and annealing temperatures differed
according to the gene as shown in Table 2). Primers were
selected using the computer program Prime3, and
designed to span at least one intron region to avoid
genomic DNA amplification.
Statistical analyses
Results are expressed as means + SEM. T-test was used. P <
0.05 was considered significant.
Conclusion
We conclude that PTTG does not correlate with prolactin
levels or tumor size in animal models prolactinoma, and
its pituitary content is not related to a decrease in
dopaminergic control of the lactotrope, but to estrogen
action at the pituitary level. Therefore it is increased only
in prolactinomas generated by estrogen treatment, and
not in prolactinomas arising from deficient dopamine
control, or in dopamine resistant compared with
dopamine responsive human prolactinomas. These
results are important in the search for reliable prognostic
indicators for patients with pituitary adenomas which will
make tumor-specific therapy possible, and help to eluci-
date the poorly understood phenomenon of pituitary
tumorigenesis.
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